CorMedix has entered into a 5-year commercial supply contract with Florida-based dialysis provider, ARC Dialysis, LLC for the supply of DefenCath. CorMedix received NDA approval of DefenCath under the Limited Population Pathway for Antibacterial and Antifungal Drugs on November 15, 2023, and expects to begin commercialization of the product in the inpatient setting on April 15th. CorMedix is committed to building meaningful long-term relationships with dialysis providers that are dedicated to innovation and infection reduction. ARC Dialysis, a Miami-based medium-sized dialysis organization, provides inpatient dialysis services to approximately 100 inpatient facilities, and is the operator of 18 outpatient dialysis units throughout Florida.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRMD:
- CorMedix Inc. Announces Commercial Agreement With ARC Dialysis, LLC
- CorMedix CEO buys 13,561 shares at $3.74
- CorMedix price target lowered to $9 from $10 at RBC Capital
- Cormedix Inc.’s DefenCath Success Hinges on Two Major Dialysis Providers: A High-Stakes Gamble in Outpatient Market Adoption
- Options Volatility and Implied Earnings Moves Today, March 12, 2024